Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Average Recommendation of “Moderate Buy” by Analysts

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has been assigned a consensus rating of “Moderate Buy” from the five analysts that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $43.80.

Several analysts have recently weighed in on INO shares. Royal Bank of Canada reduced their price objective on shares of Inovio Pharmaceuticals from $8.00 to $7.00 and set a “sector perform” rating for the company in a research report on Friday, October 4th. Oppenheimer cut their target price on shares of Inovio Pharmaceuticals from $40.00 to $33.00 and set an “outperform” rating on the stock in a report on Monday, August 12th. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $15.00 target price on shares of Inovio Pharmaceuticals in a report on Monday, July 15th.

Institutional Trading of Inovio Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of INO. SG Americas Securities LLC acquired a new stake in Inovio Pharmaceuticals in the third quarter valued at approximately $71,000. The Manufacturers Life Insurance Company acquired a new stake in Inovio Pharmaceuticals in the second quarter valued at approximately $82,000. Signature Estate & Investment Advisors LLC acquired a new stake in Inovio Pharmaceuticals in the second quarter valued at approximately $88,000. Cornercap Investment Counsel Inc. acquired a new stake in Inovio Pharmaceuticals in the second quarter valued at approximately $184,000. Finally, American Century Companies Inc. grew its position in Inovio Pharmaceuticals by 62.2% in the second quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock valued at $255,000 after acquiring an additional 12,100 shares in the last quarter. Institutional investors and hedge funds own 26.79% of the company’s stock.

Inovio Pharmaceuticals Price Performance

Shares of INO opened at $5.70 on Wednesday. Inovio Pharmaceuticals has a 1-year low of $3.89 and a 1-year high of $14.75. The stock has a market cap of $147.69 million, a PE ratio of -1.54 and a beta of 0.82. The firm has a 50-day simple moving average of $6.43 and a two-hundred day simple moving average of $8.83.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.19) EPS for the quarter, missing the consensus estimate of ($1.10) by ($0.09). The firm had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.10 million. During the same period last year, the firm posted ($1.56) earnings per share. As a group, sell-side analysts expect that Inovio Pharmaceuticals will post -4.64 earnings per share for the current fiscal year.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.